Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Jaguar Health, Inc. JAGX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$12.98
+2968.6%

Jaguar Health, Inc. (JAGX) is a Biotechnology company in the Healthcare sector, currently trading at $0.42. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is JAGX = $13 (+2968.6% upside).

Valuation: JAGX trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).

Financials: revenue is $12M, +59.1%/yr average growth. Net income is $38M (loss), growing at +13.7%/yr. Net profit margin is -329.3% (negative). Gross margin is 83.3% (+37.1 pp trend).

Balance sheet: total debt is $37M against $7M equity (Debt-to-Equity (D/E) ratio 5.01, leveraged). Current ratio is 1.63 (strong liquidity). Debt-to-assets is 68.4%. Total assets: $53M.

Analyst outlook: 5 / 5 analysts rate JAGX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$12.98
▲ 2968.56% Upside
Average Price Target
The 12-month price target for Jaguar Health, Inc. is $12.98.

JAGX SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — JAGX

✓
VALUE Pass
100/100
JAGX trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25). Analyst consensus target is $13, implying +2973.3% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
JAGX: +59.1%/yr revenue is, +13.7%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet JAGX: Debt-to-Equity (D/E) ratio 5.01 (leveraged), Current ratio is 1.63 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
JAGX: Gross margin is 83.3% (+37.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate JAGX as buy (100%). Analyst consensus target is $13 (+2973.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
JAGX: Net profit margin is -329.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.313-15.48
Volume422.35K
Avg Volume (30D)3.44M
Market Cap$986.66K
Beta (1Y)0.29
Share Statistics
EPS (TTM)-130.69
Shares Outstanding$294.53K
IPO Date2015-05-12
Employees49
CEOLisa A. Conte
Financial Highlights & Ratios
Revenue (TTM)$11.69M
Gross Profit$9.73M
EBITDA$-36.66M
Net Income$-38.49M
Operating Income$-30.83M
Total Cash$8M
Total Debt$36.53M
Net Debt$28.52M
Total Assets$53.43M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.08
Analyst Forecast
1Y Price Target$12.98
Target High$12.98
Target Low$12.98
Upside+2,968.6%
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS47010C8881

Price Chart

Track all markets on TradingView
JAGX
Jaguar Health, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.31 52WK RANGE 15.48

People Also View

ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 OCGN
OCGN
Ocugen, Inc.
$1.95
+8.33%
 ZURA
ZURA
Zura Bio Limited
$5.69
-0.52%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$14.34
+7.42%
 VXRT
VXRT
Vaxart, Inc.
$0.71
+4.41%
 ACST
ACST
Acasti Pharma Inc.
$3.37
+4.01%
 IBIO
IBIO
iBio, Inc.
$2.10
-4.11%
 ONTX
ONTX
Onconova Therapeutics, Inc.
$1.00
-0.47%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message